Last reviewed · How we verify

Tetracaine Hydrochloride (TETRACAINE)

Alcon Labs · FDA-approved approved Small molecule Verified Quality 70/100

Tetracaine Hydrochloride works by blocking sodium channels in nerve cells to prevent pain signals from being transmitted.

Tetracaine Hydrochloride, marketed by Alcon Labs, is a topical ophthalmic anesthetic currently generating revenue in a competitive market dominated by same-class drugs such as lidocaine and procaine. Its key strength lies in its mechanism of action, effectively blocking sodium channels in nerve cells to prevent pain signals, which provides reliable anesthesia for ophthalmic procedures. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics and potentially erode market share.

At a glance

Generic nameTETRACAINE
SponsorAlcon Labs
Drug classEster Local Anesthetic
TargetSodium channel protein type 7 subunit alpha
ModalitySmall molecule
Therapeutic areaNeuroscience
PhaseFDA-approved
First approval2005

Mechanism of action

Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: